186 related articles for article (PubMed ID: 15521370)
1. Patient preferences for sensory attributes of intranasal corticosteroids and willingness to adhere to prescribed therapy for allergic rhinitis: a conjoint analysis.
Mahadevia PJ; Shah S; Leibman C; Kleinman L; O'Dowd L
Ann Allergy Asthma Immunol; 2004 Oct; 93(4):345-50. PubMed ID: 15521370
[TBL] [Abstract][Full Text] [Related]
2. Willingness to pay for sensory attributes of intranasal corticosteroids among patients with allergic rhinitis.
Mahadevia P; Shah S; Mannix S; Brewster-Jordan J; Kleinman L; Liebman C; O'Dowd L
J Manag Care Pharm; 2006 Mar; 12(2):143-51. PubMed ID: 16515372
[TBL] [Abstract][Full Text] [Related]
3. Patient preferences and sensory comparisons of three intranasal corticosteroids for the treatment of allergic rhinitis.
Bachert C; El-Akkad T
Ann Allergy Asthma Immunol; 2002 Sep; 89(3):292-7. PubMed ID: 12269650
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of patients' preferences for triamcinolone acetonide aqueous, fluticasone propionate, and mometasone furoate nasal sprays in patients with allergic rhinitis.
Stokes M; Amorosi SL; Thompson D; Dupclay L; Garcia J; Georges G
Otolaryngol Head Neck Surg; 2004 Sep; 131(3):225-31. PubMed ID: 15365540
[TBL] [Abstract][Full Text] [Related]
5. Assessment of sensory perceptions and patient preference for intranasal corticosteroid sprays in allergic rhinitis.
Khanna P; Shah A
Am J Rhinol; 2005; 19(3):316-21. PubMed ID: 16011141
[TBL] [Abstract][Full Text] [Related]
6. Comparison of patient preference for sensory attributes of fluticasone furoate or fluticasone propionate in adults with seasonal allergic rhinitis: a randomized, placebo-controlled, double-blind study.
Meltzer EO; Andrews C; Journeay GE; Lim J; Prillaman BA; Garris C; Philpot E
Ann Allergy Asthma Immunol; 2010 Apr; 104(4):331-8. PubMed ID: 20408344
[TBL] [Abstract][Full Text] [Related]
7. Preferences of adult patients with allergic rhinitis for the sensory attributes of fluticasone furoate versus fluticasone propionate nasal sprays: a randomized, multicenter, double-blind, single-dose, crossover study.
Meltzer EO; Stahlman JE; Leflein J; Meltzer S; Lim J; Dalal AA; Prillaman BA; Philpot EE
Clin Ther; 2008 Feb; 30(2):271-9. PubMed ID: 18343265
[TBL] [Abstract][Full Text] [Related]
8. Formulation considerations of intranasal corticosteroids for the treatment of allergic rhinitis.
Meltzer EO
Ann Allergy Asthma Immunol; 2007 Jan; 98(1):12-21. PubMed ID: 17225715
[TBL] [Abstract][Full Text] [Related]
9. Patient preferences and sensory comparisons of three intranasal corticosteroids for the treatment of allergic rhinitis.
Sheth KK
Ann Allergy Asthma Immunol; 2003 May; 90(5):576; author reply 577. PubMed ID: 12775142
[No Abstract] [Full Text] [Related]
10. Assessment of intranasal corticosteroid use in allergic rhinitis: benefits, costs, and patient preferences.
Dupclay L; Doyle J
Am J Manag Care; 2002 Sep; 8(13 Suppl):S335-40. PubMed ID: 12243450
[TBL] [Abstract][Full Text] [Related]
11. Preference evaluation and perceived sensory comparison of fluticasone furoate and mometasone furoate intranasal sprays in allergic rhinitis.
Yonezaki M; Akiyama K; Karaki M; Goto R; Inamoto R; Samukawa Y; Kobayashi R; Kobayashi E; Hoshikawa H
Auris Nasus Larynx; 2016 Jun; 43(3):292-7. PubMed ID: 26498699
[TBL] [Abstract][Full Text] [Related]
12. Evolving paradigm in the management of allergic rhinitis-associated ocular symptoms: role of intranasal corticosteroids.
Blaiss MS
Curr Med Res Opin; 2008 Mar; 24(3):821-36. PubMed ID: 18257976
[TBL] [Abstract][Full Text] [Related]
13. Comparison of once-daily intranasal corticosteroids for the treatment of allergic rhinitis: are they all the same?
Yawn B
MedGenMed; 2006 Jan; 8(1):23. PubMed ID: 16915153
[TBL] [Abstract][Full Text] [Related]
14. Intranasal corticosteroids: the role of patient preference and satisfaction.
Sher ER; Ross JA
Allergy Asthma Proc; 2014; 35(1):24-33. PubMed ID: 24433594
[TBL] [Abstract][Full Text] [Related]
15. Effects of olopatadine hydrochloride nasal spray 0.6% in the treatment of seasonal allergic rhinitis: a phase III, multicenter, randomized, double-blind, active- and placebo-controlled study in adolescents and adults.
Shah SR; Nayak A; Ratner P; Roland P; Michael Wall G
Clin Ther; 2009 Jan; 31(1):99-107. PubMed ID: 19243710
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis and management of nasal congestion: the role of intranasal corticosteroids.
Benninger M
Postgrad Med; 2009 Jan; 121(1):122-31. PubMed ID: 19179820
[TBL] [Abstract][Full Text] [Related]
17. Optimization of intranasal corticosteroid formulations for the treatment of allergic rhinitis.
Wingertzahn MA; Derebery MJ; Nelson HS
Allergy Asthma Proc; 2007; 28 Suppl 1():S18-24. PubMed ID: 18307840
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the drug monitoring programme of azelastine hydrochloride nasal spray in the treatment of allergic rhinitis in children under 13 years of age.
Wober W; Diez Crespo CD; Bähre M
Arzneimittelforschung; 1997 Jul; 47(7):841-4. PubMed ID: 9272242
[TBL] [Abstract][Full Text] [Related]
19. Intranasal corticosteroids and allergic rhinoconjunctivitis.
Origlieri C; Bielory L
Curr Opin Allergy Clin Immunol; 2008 Oct; 8(5):450-6. PubMed ID: 18769200
[TBL] [Abstract][Full Text] [Related]
20. Open-label evaluation of azelastine nasal spray in patients with seasonal allergic rhinitis and nonallergic vasomotor rhinitis.
Lieberman P; Kaliner MA; Wheeler WJ
Curr Med Res Opin; 2005 Apr; 21(4):611-8. PubMed ID: 15899111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
